Subacute cutaneous lupus erythematosus
diseaseOn this page
Summary
Subacute cutaneous lupus erythematosus (MONDO:0015573) is a disease and 5 clinical trials. Top therapeutic interventions include litifilimab. A subtype of cutaneous lupus erythematosus — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-9 / 100 000 (United States) [Orphanet-validated]
- Phenotypes (HPO): 19
- Clinical trials: 5
Clinical features
Epidemiology
Prevalence records
2 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | 1-9 / 1 000 000 | 0.63 | United States | Validated |
| Point prevalence | 1-9 / 100 000 | 1.4805 | United States | Validated |
Signs & symptoms
Clinical features (HPO)
19 HPO clinical features (Orphanet curated; top 19 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0033555 | Anti-Ro/SS-A antibody positivity | Very frequent (80-99%) |
| HP:0000992 | Cutaneous photosensitivity | Frequent (30-79%) |
| HP:0002923 | Rheumatoid factor positive | Frequent (30-79%) |
| HP:0003493 | Antinuclear antibody positivity | Frequent (30-79%) |
| HP:0025526 | Psoriasiform lesion | Frequent (30-79%) |
| HP:0025528 | Annular cutaneous lesion | Frequent (30-79%) |
| HP:0000962 | Hyperkeratosis | Occasional (5-29%) |
| HP:0003613 | Antiphospholipid antibody positivity | Occasional (5-29%) |
| HP:0004334 | Dermal atrophy | Occasional (5-29%) |
| HP:0007417 | Discoid lupus rash | Occasional (5-29%) |
| HP:0008066 | Abnormal blistering of the skin | Occasional (5-29%) |
| HP:0020151 | Anti-dsDNA antibody positivity | Occasional (5-29%) |
| HP:0031540 | Linear IgG deposits along the epidermal basement membrane zone | Occasional (5-29%) |
| HP:0031541 | Linear C3 deposits along the epidermal basement membrane zone | Occasional (5-29%) |
| HP:0032235 | Anti-La/SS-B antibody positivity | Occasional (5-29%) |
| HP:0033558 | Anti-histone antibody positivity | Occasional (5-29%) |
| HP:0025300 | Malar rash | Very rare (<1-4%) |
| HP:0100825 | Cheilitis | Very rare (<1-4%) |
| HP:0200029 | Vasculitis in the skin | Very rare (<1-4%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | subacute cutaneous lupus erythematosus |
| Mondo ID | MONDO:0015573 |
| Orphanet | 163525 |
| ICD-10-CM | L93.1 |
| ICD-11 | 192274757 |
| NCIT | C117111 |
| SNOMED CT | 239891002 |
| UMLS | C0024140 |
| MedGen | 7403 |
| GARD | 0020042 |
| MedDRA | 10057903 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of cutaneous lupus erythematosus. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › connective tissue disorder › rheumatic disorder › lupus erythematosus › cutaneous lupus erythematosus › subacute cutaneous lupus erythematosus
Related subtypes (3): chronic cutaneous lupus erythematosus, Rowell syndrome, bullous systemic lupus erythematosus
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 5.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE3 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05531565 | PHASE2/PHASE3 | RECRUITING | A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus |
| NCT06044337 | PHASE3 | ENROLLING_BY_INVITATION | A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus |
| NCT06980805 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) |
| NCT01294774 | PHASE2 | COMPLETED | Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus |
| NCT02125695 | Not specified | COMPLETED | Pilot Tape Harvesting Study |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| LITIFILIMAB | 3 | 2 |
Related Atlas pages
- Drugs: Litifilimab